Saxon Interests Inc. Buys Shares of 14,596 CRISPR Therapeutics AG $CRSP

Saxon Interests Inc. purchased a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 14,596 shares of the company’s stock, valued at approximately $694,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Cerity Partners LLC grew its holdings in shares of CRISPR Therapeutics by 3.0% in the second quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock valued at $318,000 after purchasing an additional 190 shares in the last quarter. Peapack Gladstone Financial Corp boosted its position in CRISPR Therapeutics by 3.0% in the 2nd quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock valued at $339,000 after buying an additional 200 shares during the period. US Bancorp DE boosted its position in CRISPR Therapeutics by 4.5% in the 3rd quarter. US Bancorp DE now owns 5,777 shares of the company’s stock valued at $374,000 after buying an additional 249 shares during the period. Allworth Financial LP grew its stake in shares of CRISPR Therapeutics by 2.7% in the fourth quarter. Allworth Financial LP now owns 9,550 shares of the company’s stock worth $501,000 after acquiring an additional 249 shares in the last quarter. Finally, Meeder Advisory Services Inc. increased its position in shares of CRISPR Therapeutics by 6.6% during the fourth quarter. Meeder Advisory Services Inc. now owns 4,392 shares of the company’s stock worth $230,000 after acquiring an additional 270 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock opened at $60.77 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 17.97 and a quick ratio of 17.96. The business has a 50 day simple moving average of $53.16 and a 200-day simple moving average of $53.13. CRISPR Therapeutics AG has a 12 month low of $44.12 and a 12 month high of $78.48. The stock has a market capitalization of $5.86 billion, a PE ratio of -9.77 and a beta of 1.71.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The firm had revenue of $1.46 million during the quarter. Equities analysts predict that CRISPR Therapeutics AG will post -4.89 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on CRSP. Evercore restated an “outperform” rating and issued a $76.00 price objective on shares of CRISPR Therapeutics in a report on Monday, May 11th. Wall Street Zen downgraded shares of CRISPR Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Morgan Stanley set a $60.00 price target on CRISPR Therapeutics and gave the company an “equal weight” rating in a research note on Thursday, June 11th. UBS Group set a $80.00 price target on CRISPR Therapeutics in a report on Friday, June 12th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $67.78.

Insider Buying and Selling

In related news, insider Naimish Patel sold 3,786 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the sale, the insider directly owned 19,357 shares in the company, valued at $1,076,636.34. The trade was a 16.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.